Tiverton Asset Management LLC decreased its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 25.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,624 shares of the biotechnology company’s stock after selling 10,674 shares during the quarter. Tiverton Asset Management LLC owned 0.11% of Atara Biotherapeutics worth $443,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Atara Biotherapeutics in the first quarter valued at approximately $132,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Atara Biotherapeutics in the first quarter worth $185,000. State of Wisconsin Investment Board acquired a new position in shares of Atara Biotherapeutics in the second quarter worth $252,000. American International Group Inc. grew its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares in the last quarter. Finally, IndexIQ Advisors LLC acquired a new position in shares of Atara Biotherapeutics in the second quarter worth $323,000. 82.95% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/17/atara-biotherapeutics-inc-atra-shares-sold-by-tiverton-asset-management-llc.html.

In related news, EVP Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock in a transaction on Monday, July 17th. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00. Following the sale, the executive vice president now owns 362,080 shares of the company’s stock, valued at approximately $5,402,233.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mitchall G. Clark sold 3,021 shares of Atara Biotherapeutics stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $14.33, for a total transaction of $43,290.93. The disclosure for this sale can be found here. Insiders have sold a total of 43,509 shares of company stock worth $650,342 in the last ninety days. 16.10% of the stock is currently owned by insiders.

Several equities analysts have commented on ATRA shares. Jefferies Group LLC restated a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $25.50.

Atara Biotherapeutics, Inc. (ATRA) opened at 15.65 on Friday. The company’s 50 day moving average is $14.69 and its 200-day moving average is $15.87. The firm’s market cap is $478.25 million. Atara Biotherapeutics, Inc. has a 52 week low of $11.80 and a 52 week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05). Equities analysts expect that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.